Last edition
News about "Small Lymphocytic Lymphoma (SLL)"
US FDA Approves Pirtobrutinib for Untreated CLL/SLL
The US FDA has approved Eli Lilly’s pirtobrutinib (Jaypirca) for previously untreated CLL/SLL in adults without known 17p deletion.
Small Lymphocytic Lymphoma (SLL) | 05/10/2026 | By News Bureau
China Approves Jaypirca for Relapsed CLL and SLL Patients
Jaypirca (pirtobrutinib) by Innovent Biologics has been approved in China for the treatment of adults with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The BTK inhibitor is designed to overcome resistance associated with prior covalent BTK therapies.
Small Lymphocytic Lymphoma (SLL) | 02/03/2026 | By News Bureau | 198
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy